GHK

Glycyl-L-Histidyl-L-Lysine, commonly known as GHK, is a naturally occurring tripeptide found in human plasma, saliva, and urine. It is often studied in the context of its copper-binding form, GHK-Cu. This tripeptide is believed to play a role in tissue repair, wound healing, and anti-aging processes. GHK functions as a carrier peptide, facilitating the transport of copper ions, which are essential for various biological functions, including the activation of enzymes involved in collagen and elastin production. The proposed mechanism of action involves GHK-Cu's ability to stimulate collagen synthesis, promote angiogenesis (formation of new blood vessels), and modulate inflammation. It is also theorized to influence gene expression, potentially affecting cellular processes related to tissue regeneration and protection.

The current research landscape surrounding GHK is varied, encompassing both in vitro and in vivo studies, as well as a number of clinical trials. A search of clinical trial databases reveals studies investigating GHK in diverse contexts. For example, one Phase 1 trial, which has been terminated, aimed to study the application of the QRH-882260 heptapeptide in the colon, potentially involving GHK or related peptides. Another study, "Amino Acids Expression Profiling of Patients With Sepsis," sponsored by the Chinese PLA General Hospital, is an ongoing, non-blinded trial with 100 participants. While the direct involvement of GHK in this trial is not explicitly stated, the study's focus on amino acid profiling suggests a potential investigation into the role of peptides in sepsis. A completed Phase 4 trial, "Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy," involved 50 participants and was sponsored by the University of Ioannina, but it is unclear how GHK relates to the trial's focus on dapagliflozin and renal function. Furthermore, large-scale studies like "Generation Healthy Kids," a cluster-randomized trial with over 1300 participants, and "Microbial Enzyme Impact on Postprandial Nutrient Levels and Gastrointestinal Symptoms in Healthy Adults" with 30 participants, suggest the broad range of contexts where peptide research, potentially including GHK, is being explored.

A review paper with 368 citations, "Protective Functions of β-Alanyl-L-Histidine and Glycyl-L-Histidyl-L-Lysine Glycoconjugates and Copper in Concert," highlights the antioxidant and protective roles of GHK in conjunction with copper. Other research papers explore diverse applications, such as the use of resorbable organic sensors for monitoring intestinal ischemia ("Real-Time In Vivo Monitoring of Anastomotic Intestinal Ischemia Using Implantable Resorbable Organic Sensors," 58 citations) and the impact of road traffic noise on DNA methylation ("Road traffic noise exposure and blood DNA methylation at birth and in childhood: An epigenome-wide meta-analysis," 57 citations), suggesting the breadth of research areas where GHK or related compounds are being investigated.

The safety profile of GHK appears relatively favorable based on available data. The FDA adverse event reporting system (FAERS) contains a single report associated with GHK, with reactions including anaphylactic shock, decreased blood pressure and heart rate, flushing, and hyperhidrosis. However, the lack of serious classifications suggests that severe adverse events are rare.

GHK is currently unregulated and is not FDA-approved for any specific therapeutic use. It is commonly used in cosmetic products and dietary supplements, particularly those marketed for skin health, anti-aging, and wound healing. Individuals seeking to improve skin appearance, reduce wrinkles, or accelerate wound healing are typical consumers of products containing GHK.

Given the unregulated status and the ongoing research into its potential benefits and mechanisms, the future of GHK lies in further robust clinical trials to validate its efficacy and safety for specific applications, which could influence its regulatory outlook.